Newsletters


Filter by volume

Agenus on Twitter

We are thrilled to be collaborating with @targovax, advancing I-O agents in pursuit of improving safety and outcomes for patients in need twitter.com/targovax/statu…

$AGEN Corporate Update and First Quarter 2022 Financial Report investor.agenusbio.com/news-releases/…

The latest $AGEN Newsletter is now available! Here we highlight AGEN1571, our novel antibody targeting ILT2, which we presented data on at #AACR2022. Our IND has been cleared & we expect clinical trials to begin this year. Learn more: agenusbio.com/newsletters/ag…

Agenus’ CD137 Agonist (AGEN2373) Advances in the Clinic, Triggering Milestone Payment from Gilead investor.agenusbio.com/news-releases/…

test Twitter Media - Agenus’ CD137 Agonist (AGEN2373) Advances in the Clinic, Triggering Milestone Payment from Gilead

https://t.co/Rklgt2nxk8 https://t.co/4XshIfxh6y

MiNK Therapeutics Announces Patients Dosed with AgenT-797 iNKT Cell Therapy in Solid Tumor Cancers investor.minktherapeutics.com/news-releases/… Retweeted by Agenus Inc. ($AGEN)

$AGEN featured in the 2022 “Scrip Asks” series where industry executives discuss therapeutic area advances - read @ODayMD discuss how our next-generation CTLA-4 antibody could enhance the possibilities of immunotherapy. @ScripEleanor scrip.pharmaintelligence.informa.com/SC145964/Scrip…

UroGen submits IND application supporting planned Phase 1 clinical study of UGN-301 (zalifrelimab) intravesical solution in recurrent non-muscle invasive bladder cancer investors.urogen.com/news-releases/…

Agenus Corporate Update and Fourth Quarter & Full Year 2021 Financial Report investor.agenusbio.com/news-releases/…

Read $AGEN featured in @statnews, where @dhanschand discusses the importance and potential of TGF-beta in I-O, and our anti-TGF-beta program AGEN1423. statnews.com/2022/02/17/tgf…

The latest Agenus newsletter is now available. Agenus is positioned to launch into a year of dynamic advancement in 2022 - with new clinical data, portfolio expansion, and international impact. Read more about our focus on key value drivers in 2022: agenusbio.com/newsletters/ag…

Hear Dr. Steven O’Day join a panel discussion hosted by @Endpts to review the potential of emerging #checkpoint targets at 2pm EST on 1/27! @ODayMD #immunooncology #cancer #lifesciences webinars.endpts.com/the-checkpoint…

Read @garo_armen and other industry leaders express their thoughts on what the future might hold for #immunotherapies in #cancer in this story by @jasonmmast and @endpts. #oncology twitter.com/Jasonmmast/sta…

This year, we look forward to accelerating development of our pipeline to broaden the reach of immunotherapies to more patients & tumor types. @omalleygynonc highlights the durable responses induced by our CTLA-4 antibody candidates in many GYN cancers: targetedonc.com/view/sitc-2021…

Bal/Zal Phase 2 cervical cancer trial results published in Journal of Clinical Oncology; 26% ORR (33% ORR in PD-L1+ patients), mDoR not reached after 21 months of follow-up. Click here to read more: investor.agenusbio.com/news-releases/…

$AGEN has been named to the Boston Business Journal’s list of 2021 Middle Market Leaders, their 50 highest growth middle-market companies in MA. We are thrilled to be nominated and look forward to further growth and progress next year. @BosBizJournal bizjournals.com/boston/news/20…

Rottapharm Biotech Clinical Collaboration: An important step for treatment-resistant colorectal cancer The 1st patient has been dosed in their Ph 1/2 study of CR6086 combined with balstilimab in advanced CRC. Read the latest $AGEN newsletter here: agenusbio.com/newsletters/ag…

@dhanschand, $AGEN Scientific Director Head of Drug Discovery, is speaking today at the 2nd Annual TIGIT Therapies Digital Summit on the panel session “Fc binding for Effector Function: What have we Learnt?” Register to watch at 12:30 PM ET! tigit-therapies.com/speaker/dhan-c…

test Twitter Media - @dhanschand, $AGEN Scientific Director Head of Drug Discovery, is speaking today at the 2nd Annual TIGIT Therapies Digital Summit on the panel session “Fc binding for Effector Function: What have we Learnt?” Register to watch at 12:30 PM ET! 

https://t.co/BBAKlXVLGi https://t.co/3rv3r8uhTv

Tune in today at 1:50PM ET for our fireside chat by @garo_armen and @ODayMD at the annual Evercore ISI HealthCONX Conference: wsw.com/webcast/everco…

The latest Agenus Newsletter is now available! AGEN1181 Achieves Responses Across 9 Cancers: Seventeen Objective Responses as Single Agent or in Combination with Balstilimab agenusbio.com/newsletters/ag…

Tune in today to hear @dhanschand and @ODayMD at the B. Riley Fall 2021 Growth Biotech Best Ideas Series, including the latest #AGEN1181 clinical data from #SITC21 investor.agenusbio.com/events/event-d…

test Twitter Media - Tune in today to hear @dhanschand and @ODayMD at the B. Riley Fall 2021 Growth Biotech Best Ideas Series, including the latest #AGEN1181 clinical data from #SITC21 

https://t.co/wB0kWxRkkG https://t.co/yO0D7n2Al0